heart

Designer Drug Uses Double Whammy to Fight Heart Disease

Custom-Built Molecule May Improve On Its Natural Counterpart

plaque buildup in an artery

Ten years ago, a young woman from Chicago came to the National Institutes of Health with a rare genetic condition. A mutation in her DNA was making her metabolic system malfunction, causing levels of fat molecules called triglycerides in her blood to skyrocket far out of the normal range. This triggered inflammation in her pancreas, a painful and potentially life-threatening condition known as pancreatitis. She couldn’t understand why there wasn’t any kind of treatment to help her.

IRP senior investigator Alan T. Remaley, M.D., Ph.D., took on the challenge with the help of Anna Wolska, Ph.D., a research fellow in his lab. Dr. Remaley leads the Lipoprotein Metabolism Section in the National Heart, Lung, and Blood Institute (NHLBI), where he and Dr. Wolska study lipoproteins, small particles that transport fats such as cholesterol and triglycerides through the bloodstream to be broken down and used by cells for energy. Their efforts to help that young woman ultimately led to the discovery — published last January — of a new strategy for reducing triglycerides in order to treat serious ailments like pancreatitis and heart disease.

Modified Hormone Protects Damaged Hearts

Alteration Helps Prospective Drug Persist Longer in Rodents’ Bodies

transparent view of the body with heart highlighted

Even the best construction crew cannot repair a building if it is called away from the site before it can begin its work. Similarly, while the body’s ability to cleanse itself of chemicals can prevent the buildup of toxins, it can also stymie the therapeutic effects of medications. IRP researchers recently found that modifying a prospective treatment for heart failure to help it persist longer in the body boosted its beneficial effects in mice.

A Look Back at the Legacy of Theodor Kolobow

The IRP has been home to a number of truly remarkable scientists who spent decades making discoveries and developing technologies that would go on to improve the lives of many. One of these giants was Theodor Kolobow, M.D., who passed away in March of last year at age 87. During his many years at the NIH's National Heart, Lung, and Blood Institute (NHLBI), Dr. Kolobow made momentous contributions to the study of our lungs and cardiovascular systems, including advancements in the development of artificial organs and key insights into the biological processes behind acute lung injury. 

Dr. Kolobow's legacy lives on not only through his colleagues' fond memories and his lasting influence on medical practice, but also through the NIH's historical archives. Read on for a tour through Dr. Kolobow's life and career, as can only be told by the Office of NIH History. 

Dr. Theodor Kolobow

NIH Heart Surgery Artifacts – Aortic Valve Bypass Assembly

Pieces from aortic valve bypass assemblies

Sometimes as a museum curator, I come across a box in the collection with a vague marking and full of bits and pieces of … something. One of the coolest things is finding out what that something was and who created it. This photo shows pieces from the NIH lab of Dr. Stanley Sarnoff, dating from 1954-1962.

Real-Time MRI Upgrades Heart Surgery

Using real-time MRI, Dr. Keith Horvath's group at the NIH's National Heart, Lung, and Blood Institute (NHLBI) can precisely implant a replacement porcine heart valve using a collapsible stent more safely and quickly than with standard techniques.

"The reason for using [real-time] MRI is three-fold," Dr. Horvath explains...

Keith Horvath real time MRI Imaging